Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Barclays PLC

Barclays PLC increased its stake in shares of Replimune Group, Inc. (NASDAQ:REPL) by 165.5% in the third quarter, HoldingsChannel reports. The firm owned 158,491 shares of the company’s stock after buying an additional 98,791 shares during the quarter. Barclays PLC’s holdings in Replimune Group were worth $1,738,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp boosted its stake in shares of Replimune Group by 102.1% during the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after purchasing an additional 1,182,181 shares during the last quarter. Parkman Healthcare Partners LLC boosted its position in Replimune Group by 45.5% during the third quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company’s stock worth $8,371,000 after acquiring an additional 238,747 shares during the last quarter. Arizona PSPRS Trust purchased a new stake in Replimune Group in the 3rd quarter worth approximately $834,000. Baker BROS. Advisors LP raised its holdings in Replimune Group by 10.0% in the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock valued at $121,057,000 after acquiring an additional 1,000,000 shares during the last quarter. Finally, Erste Asset Management GmbH purchased a new position in shares of Replimune Group during the 3rd quarter worth $133,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Jefferies Financial Group lifted their price objective on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. JPMorgan Chase & Co. upped their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th. BMO Capital Markets boosted their target price on shares of Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a report on Friday, November 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $17.00 price target on shares of Replimune Group in a research note on Friday, November 22nd. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $17.29.

Insider Activity

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $12.42, for a total value of $124,200.00. Following the transaction, the chief executive officer now directly owns 202,014 shares of the company’s stock, valued at $2,509,013.88. This represents a 4.72 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the sale, the insider now directly owns 109,885 shares of the company’s stock, valued at $1,184,560.30. The trade was a 6.19 % decrease in their position. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

Replimune Group Price Performance

REPL opened at $12.26 on Friday. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. The company has a market cap of $838.79 million, a P/E ratio of -4.02 and a beta of 1.26. The company has a 50 day moving average of $12.37 and a two-hundred day moving average of $10.86. Replimune Group, Inc. has a 52-week low of $4.92 and a 52-week high of $17.00.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. On average, analysts expect that Replimune Group, Inc. will post -2.91 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.